The biologics license application for toripalimab will undergo a speedy review by the FDA for consideration as a frontline treatment option for patients with advanced recurrent or metastatic nasopharyngeal carcinoma in combination with gemcitabine and cisplatin, and as a single-agent for the second-line or above treatment of recurrent or metastatic disease after platinum-containing chemotherapy.
The FDA is considering an application parsaclisib as treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, and granted priority review for 2 of the 3 indications.
Extended follow-up of patients in COSMIC-311 showed continued survival benefit and tumor reduction with cabozantinib versus placebo in patients with radioactive iodine-refractory differentiated thyroid cancer.
Two approvals for asciminib were issued by the FDA for the treatment of CML with a Ph+ mutation.
In a phase 1 dose-escalation study, an investigational BTK degrader showed clinically meaningful results in patients with chronic lymphocytic leukemia and elicited a response.
Retrospective data suggest that perinephric fat invasion, sarcomatoid or rhabdoid component, and necrosis are independent prognostic indicators of recurrence-free survival in renal cell carcinoma.
A gene therapy development initiative from the FDA, National Institute of Health and 15 other organizations may move CRISPR closer to use in patients with rare cancers.
Efficacy observed with the combination of devimistat and modified FOLFIRINOX in patients with metastatic pancreatic cancer has lead to a negative result in the phase 3 AVENGER 500 clinical trial.
After discovering the potential of a prophylactic breast cancer vaccine, Cleveland Clinic will be the site of a phase 1 clinical trial to test its safety.
The FDA has accepted a biologics license application for tisagenlecleucel and granted it priority review as a potential treatment for relapsed or refractory follicular lymphoma after 2 lines of therapy
Topline results show that the addition of eryaspase to chemotherapy does not prolong survival in the general advanced pancreatic cancer population, but there may be benefit for those treated with irinotecan.
The phase CANOPY-1 study has missed its co primary end points, but signals observed in a non–small cell lung cancer subgroup warrant further investigation.
Significant survival improvement was achieved with durvalumab in combination with chemotherapy as treatment of patients with biliary tract cancer.
With a fast track designation for platinum-resistant ovarian cancer, development of the agent in this disease state will be expedited to potentially fill an unmet medical need.
Good activity was seen with acalabrutinib in combination with venetoclax and obinutuzumab in the front-line setting for select patients with chronic lymphocytic leukemia.
The primary end point of the phase 3 SOLSTICE study of trifluridine and tipiracil plus bevicizumab versus capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer was not met.
Both the primary and key secondary end point of the phase 3 EMERALD study have been reached.
In an interview with Targeted Oncology, Evanthia Roussos Torres, MD, PhD, discussed the phase 1 investigation of the safety and efficacy of entinostat administered in combination with nivolumab and ipilimumab for the treatment of advanced HER2-negative breast cancer.
In a randomized study, geriatric assessment-driven intervention was effective in reducing chemotherapy-related toxicities in older patients with cancer.
Following treatment with chimeric antigen receptor T-cell therapy, patients with relapsed or refractory large B-cell lymphoma require more options. Investigators are now evaluating an interleukin-17 agent.
Despite the success of implementing maintenance therapy in other leukemias, the key challenge with administering maintenance therapy in acute myeloid leukemia has been identifying an effective drug.
A phase 1b/2 study has shown an 80% clinical activity rate with liposomal annamycin as treatment of soft tissue sarcoma lung metastases.
New findings from the phase 3 monarchE recently led to an FDA approval for abemaciclib. Joyce O’Shaughnessy, MD, presented the long-term analysis results during an ESMO Virtual Plenary.
The future of minimal residual disease testing in chronic lymphocytic leukemia may be applicable for patients being treated with venetoclax in combination with Bruton’s tyrosine kinase inhibitors.
In an interview with Targeted Oncology, Alice S. Mims, MD, discussed targeting biomarkers in acute myeloid leukemia, and upfront disease management.
The HIMALAYA study has met its primary end point of overall survival improvement in patients with unresectable hepatocellular carcinoma with tremelimumab plus durvalumab.
During the NCCN 2021 Congress: Hematologic Malignancies, Aaron T. Gerds, MD, MS, explained the risk stratification tools used in patients with myeloproliferative neoplasms.
Atezolizumab is now approved for the adjuvant treatment of NCSLC expressing PD-L1≥1%. The approval is based on the IMpower010 study.
Currently, no FDA-approved therapies are available to address the need of patients with advanced/recurrent endometrial cancer, underscoring a need to develop novel strategies like the combination of lenvatinib and weekly paclitaxel.
75-year-old man presented with fever, a 7-lb unintentional weight loss, and occasional chest pain.